3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Motor Activity
9
Neoplasms
4
Breast Neoplasms
3
Weight Loss
2
Ventricular Dysfunction, Left
1
Urinary Incontinence
1
Sexual Dysfunction, Physiological
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Melanoma
1
Lymphoma
1
Leukemia
1
Insulin Resistance
1
Hypoxia
1
Hematologic Neoplasms
1
Heart Failure
1
Head and Neck Neoplasms
1
Fecal Incontinence
1
Fatigue
1
Cardiotoxicity
1
Carcinoma, Renal Cell
1
Cachexia
1
Brenner Tumor
1
Breast Diseases
1
Brain Neoplasms
1
Bone Metastases
1
Body Weight
1
Interventions
Sunitinib
27
Nivolumab
26
pembrolizumab
23
Sorafenib
17
Everolimus
14
Cyclophosphamide
13
Interleukin-2
10
Bevacizumab
10
Radiosurgery
9
spartalizumab
8
pazopanib
7
atezolizumab
7
Ipilimumab
7
Axitinib
7
fludarabine
6
aldesleukin
6
cabozantinib
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Immunohistochemistry
5
Gemcitabine
5
peginterferon alfa-2b
4
avelumab
4
Nephrectomy
4
Irinotecan
4
Introns
4
Gene Expression Profiling
4
Capecitabine
4
lenvatinib
3
fludarabine phosphate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Renal Cell
×
Exercise
×
Clear all
NCT03692338
2019-12-18
INTERVAL
Duke University
Phase NA
Terminated
2 enrolled